GlassScriptPhysician profile
Shannon Weaver
NPI 1457903791
$7,389.29
in general payments reported to CMS, 2019-2025
45 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,713 · 2022: $1,305 · 2023: $1,331 · 2024: $1,974 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,179 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,178.88 |
| Education | $192.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,124.48 | 2021-2025 | |
| Astellas Pharma US INC | $715.25 | 2021-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $487.37 | 2021-2025 | Trelegy Ellipta, Arexvy, Benlysta |
| Pfizer INC. | $481.86 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $457.13 | 2022-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.54 | 2021-2025 | Jardiance |
| Amgen INC. | $313.72 | 2022-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $289.03 | 2021-2024 | |
| Novo Nordisk INC | $288.35 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Amarin Pharma, INC. | $283.05 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.73 | 2021-2022 | |
| Lilly USA, LLC | $247.99 | 2021-2024 | Jardiance, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $214.34 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Biotech, INC. | $205.82 | 2025 | Tremfya |
| Biohaven Pharmaceuticals, INC. | $195.80 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.